Reported changes in sexual behaviour and human papillomavirus knowledge in Peruvian female sex workers following participation in a human papillomavirus vaccine trial

B. Brown, M. M. Blas, O. Heidari, C. Carcamo, N. A. Halsey

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Limited data exist on the effect of clinical trial participation on sexual behavioural change. Two hundred female sex workers working in Lima, Peru received human papillomavirus (HPV) vaccine in either the standard (0, 2, 6 months) or modified (0, 3, 6 months) schedule. Participants received comprehensive screening and treatment for sexually transmitted infections (STIs), counselling on safe sex practices, education about HPV and the HPV vaccine, contraceptives (oral and condoms) and family planning at each visit. We assessed vaccine completion rates, change in sexual practices, and changes in HPV knowledge before and after participation in the vaccine trial. There were high rates of vaccine completion, 91% overall. The estimated number of reported new and total clients over a 30-day period decreased significantly (P < 0.001). Knowledge about HPV and HPV-related disease increased among all participants. In addition, all participants listed at least one preventive strategy during the month 7 follow-up survey.

Original languageEnglish (US)
Pages (from-to)531-535
Number of pages5
JournalInternational Journal of STD and AIDS
Volume24
Issue number7
DOIs
StatePublished - Apr 2013
Externally publishedYes

Keywords

  • HIV
  • HPV vaccine
  • Peruvian female sex workers
  • human papillomavirus
  • prevention
  • sexual risk behaviour
  • sexually transmitted infections

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Reported changes in sexual behaviour and human papillomavirus knowledge in Peruvian female sex workers following participation in a human papillomavirus vaccine trial'. Together they form a unique fingerprint.

Cite this